(secondQuint)Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress.

 The introduction of atypical antipsychotics has created a renewed interest in adjunctive therapy for MDD, particularly for treatment-resistant MDD.

 Several atypical antipsychotics have been shown to enhance the response to ADT.

 This is a phase 3, multicenter, randomized, double-blind, placebo-controlled, fixed-dose trial designed to assess the safety and efficacy of brexpiprazole (2.

0 mg/day) as adjunctive therapy to an assigned open-label ADT in depressed subjects with and without anxious distress.

.

 Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress@highlight

The purpose of this study is to assess the tolerability, safety, and efficacy of brexpiprazole (2.

0 mg/day) as adjunctive therapy in adult subjects with a diagnosis of MDD with and without anxious distress